Tag Archives: EGFR mutations

Boehringer Ingelheim announces results of LUX-Lung 7 trial for treatment of patients with advanced non-small cell lung cancer with EGFR mutations

Posted on 1, February 2016 by

• Results of global Phase IIb LUX-Lung 7 trial demonstrate afatinib superior in reducing the risk of lung cancer progression and the risk of treatment failure both by 27% compared to gefitinib1 • More patients on afatinib were free of … Read the full press release →

Posted in Germany, Healthcare, Pharma & Biotech

Tagged , ,